Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 424

1.

The presence of HLA-directed antibodies after heart transplantation is associated with poor allograft outcome.

Tambur AR, Pamboukian SV, Costanzo MR, Herrera ND, Dunlap S, Montpetit M, Heroux A.

Transplantation. 2005 Oct 27;80(8):1019-25.

PMID:
16278580
2.

Flow cytometric detection of HLA-specific antibodies as a predictor of heart allograft rejection.

Tambur AR, Bray RA, Takemoto SK, Mancini M, Costanzo MR, Kobashigawa JA, D'Amico CL, Kanter KR, Berg A, Vega JD, Smith AL, Roggero AL, Ortegel JW, Wilmoth-Hosey L, Cecka JM, Gebel HM.

Transplantation. 2000 Oct 15;70(7):1055-9.

PMID:
11045642
3.

Development of an antibody specific to major histocompatibility antigens detectable by flow cytometry after lung transplant is associated with bronchiolitis obliterans syndrome.

Palmer SM, Davis RD, Hadjiliadis D, Hertz MI, Howell DN, Ward FE, Savik K, Reinsmoen NL.

Transplantation. 2002 Sep 27;74(6):799-804.

PMID:
12364858
4.

Utility of post-transplant anti-HLA antibody measurements in pediatric cardiac transplant recipients.

Xydas S, Yang JK, Burke EM, Chen JM, Addonizio LJ, Mital SR, Itescu S, Hsu DT, Lamour JM.

J Heart Lung Transplant. 2005 Sep;24(9):1289-96.

PMID:
16143247
5.
6.

Utility of posttransplantation panel-reactive antibody measurements for the prediction of rejection frequency and survival of heart transplant recipients.

George JF, Kirklin JK, Shroyer TW, Naftel DC, Bourge RC, McGiffin DC, White-Williams C, Noreuil T.

J Heart Lung Transplant. 1995 Sep-Oct;14(5):856-64.

PMID:
8800720
7.

Poor graft outcome in recipients with de novo donor-specific anti-HLA antibodies after living related kidney transplantation.

Li X, Ishida H, Yamaguchi Y, Tanabe K.

Transpl Int. 2008 Dec;21(12):1145-52. doi: 10.1111/j.1432-2277.2008.00755.x. Epub 2008 Sep 17.

8.

Donor-specific HLA alloantibodies: long-term impact on cardiac allograft vasculopathy and mortality after heart transplant.

Kaczmarek I, Deutsch MA, Kauke T, Beiras-Fernandez A, Schmoeckel M, Vicol C, Sodian R, Reichart B, Spannagl M, Ueberfuhr P.

Exp Clin Transplant. 2008 Sep;6(3):229-35.

9.

Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome.

Worthington JE, Martin S, Al-Husseini DM, Dyer PA, Johnson RW.

Transplantation. 2003 Apr 15;75(7):1034-40.

PMID:
12698094
10.

Relevance of posttransplant flow cytometric T- and B-cell crossmatches in tacrolimus-treated renal transplant patients.

Lenaers JI, Christiaans MH, Voorter CE, van Hooff HP, van den Berg-Loonen EM.

Transplantation. 2006 Nov 15;82(9):1142-7.

PMID:
17102764
11.

Anti-HLA antibody analysis and crossmatching in heart and lung transplantation.

Reinsmoen NL, Nelson K, Zeevi A.

Transpl Immunol. 2004 Jun-Jul;13(1):63-71. Review.

PMID:
15203130
12.

Aortic valve allograft structural deterioration is associated with a subset of antibodies to human leukocyte antigens.

Dignan R, O'Brien M, Hogan P, Thornton A, Fowler K, Byrne D, Stephens F, Harrocks S.

J Heart Valve Dis. 2003 May;12(3):382-90; discussion 390-1.

PMID:
12803340
13.

Detection of anti-HLA antibody by flow cytometry in patients with a left ventricular assist device is associated with early rejection following heart transplantation.

DeNofrio D, Rho R, Morales FJ, Kamoun M, Kearns J, Dorozinsky C, Rosengard BR, Acker MA, Loh E.

Transplantation. 2000 Mar 15;69(5):814-8.

PMID:
10755532
14.

Pre- and posttransplantation allosensitization in heart allograft recipients: major impact of de novo alloantibody production on allograft survival.

Ho EK, Vlad G, Vasilescu ER, de la Torre L, Colovai AI, Burke E, Deng M, Schwartz J, Marboe C, Mancini D, Opelz G, Suciu-Foca N.

Hum Immunol. 2011 Jan;72(1):5-10. doi: 10.1016/j.humimm.2010.10.013. Epub 2010 Nov 10.

PMID:
20971146
15.

Antibodies against donor human leukocyte antigens and the outcome of cardiac allografts in adults and children.

Stastny P, Lavingia B, Fixler DE, Yancy CW, Ring WS.

Transplantation. 2007 Sep 27;84(6):738-45.

PMID:
17893607
16.
17.

Preformed IgG antibodies against major histocompatibility complex class II antigens are major risk factors for high-grade cellular rejection in recipients of heart transplantation.

Itescu S, Tung TC, Burke EM, Weinberg A, Moazami N, Artrip JH, Suciu-Foca N, Rose EA, Oz MC, Michler RE.

Circulation. 1998 Aug 25;98(8):786-93.

18.

Impact of ELISA-detected anti-HLA antibodies on pediatric cardiac allograft outcome.

Di Filippo S, Girnita A, Webber SA, Tsao S, Boyle GJ, Miller SA, Gandhi SK, Zeevi A.

Hum Immunol. 2005 May;66(5):513-8. Epub 2005 Feb 26.

PMID:
15935888
19.

De novo donor HLA-specific antibodies after heart transplantation are an independent predictor of poor patient survival.

Smith JD, Banner NR, Hamour IM, Ozawa M, Goh A, Robinson D, Terasaki PI, Rose ML.

Am J Transplant. 2011 Feb;11(2):312-9. doi: 10.1111/j.1600-6143.2010.03383.x. Epub 2011 Jan 10.

20.

Supplemental Content

Support Center